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Abstract
In the last few years, the treatment of spinal metastases has significantly changed. This is due to the advancements in surgical
technique, radiotherapy, and chemotherapy which have enriched the multidisciplinary management. Above all, the field of
molecular biology of tumors is in continuous and prosperous evolution. In this review, the molecular markers and new
approaches that have radically modified the chemotherapeutic strategy of the most common metastatic neoplasms will be
examined together with clinical and surgical implications. The experience and skills of several different medical professionals are
mandatory: an interdisciplinary oncology team represents the winning strategy in the treatment of patients with spinal metastases
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Introduction
In recent years, the treatment of spinal metastases has changed
significantly due to the advancements in surgical technique,
radiotherapy, and chemotherapy which have enriched the
now-essential multidisciplinary management of these patients.
The development of new minimally invasive surgical tech-
niques has reduced complications related to surgery, even in
more aggressive approaches.1 Stereotactic radiotherapy has
taken a leading role compared to traditional radiation tech-
niques.2 Finally, and probably most importantly, chemotherapy
has evolved, providing greater efficacy in durable control of
systemic disease, thus changing the paradigm of management.3
The identification of multiple molecular markers, which can
be exploited as therapeutic targets, has led to a more tailored
approach, with tangible improvements in overall survival (OS),
progression-free survival (PFS), and quality of life. The field of
molecular biology of tumors is in continuous and prosperous
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evolution. This review will examine the molecular markers and
novel approaches that have radically modified the chemother-
apeutic strategy of the most common metastatic neoplasms.
The most recent literature updates will be examined for each
tumor type, and clinical implications will be discussed.
Methods
A comprehensive search was performed on PubMed, Clinical-
Trials.gov, and oncology conference websites, using the search
terms “lung cancer,” “breast cancer,” “prostate cancer,”
“melanoma,” “renal cell cancer,” “thyroid cancer,”
“hepatocellular carcinoma,” “colorectal cancer,” “metastases,”
“spine metastases,” “molecular markers,” “targeted therapy,”
“immunotherapy,” and “immune checkpoint inhibitors.” Only
papers published in English were reviewed. Papers were
included if they related to the scope of this review.
Tumor types
Lung Cancer
Lung cancer is the most common neoplasm, and metastatic
disease is very frequent at diagnosis.4 Histologically, lung can-
cer is broadly divided into small cell lung cancer (SCLC) and
non-small cell lung cancer (NSCLC).
Medical treatment for NSCLC improved dramatically dur-
ing the last few years, thanks to the discovery of new molecular
targets.4,5 It has been reported that up to 60% of lung adeno-
carcinomas and 50% to 80% of lung squamous cell carcinomas
harbor gene mutations in protein kinases or other membrane
receptors.5 New therapies have thus been developed in the form
of tyrosine kinase inhibitors (TKIs) and monoclonal antibodies
directed against specific receptors.
The mutation of epithelial growth factor receptor (EGFR) is
a known predictor of clinical benefit in patients with NSCLC.4-
11 Epithelial growth factor promotes cellular proliferation and
contrasts apoptosis. The EGFR TKIs (Gefitinib, Erlotinib, Afa-
tinib, and Osimertinib), in patients with specific mutations,
enhance apoptosis while conversely decreasing cell growth,
metastases, and angiogenesis.12 Mutation in EGFR is more
common in adenocarcinomas, nonsmokers, Asian patients, and
females.13 The TKIs (eg, Gefitinib) ensured a longer PFS com-
pared to traditional chemotherapy; without EGFR mutation,
PFS was longer in the chemotherapy group.13,14 Median OS
improved up to 24 to 36 months with EGFR inhibitors.15
A common drug resistance mechanism is the T790M sec-
ondary mutation of EGFR.16 Afatinib was developed as a
second-generation inhibitor against EGFR and human epider-
mal growth factor receptors 2 and 4 (HER2 and HER4), but its
effectiveness was not superior to previous EGFR TKIs.17 A
third-generation EGFR TKI, Osimertinib, was effective in
T790Mþ advanced NSCLC.18
Anaplastic lymphoma kinase (ALK), another tyrosine
kinase receptor, is fused in a small percentage of cases with
NSCLC (3%-7%) to the echinoderm microtubule-associated
protein-like 4 (EML4) creating the so-called ALK-EML4
fusion oncogene or ALK rearrangement, which promotes cell
growth and proliferation.16 In these cases, a new generation of
ALK inhibitors (after Crizotinib) is available (Ceritinib, Briga-
tinib, and Alectinib) and has become the treatment of choice.5
This mutation is usually detected in younger patients who have
never smoked and in patients with adenocarcinomas.5,16
Angiogenesis is a hallmark of most neoplasms. In lung can-
cer, Bevacizumab, inhibiting the vascular endothelial growth
factor A (VEGF-A), is the most effective of all angiogenesis
inhibitors and promotes tumoral cavitation.19 In squamous cell
carcinomas, it increases the risk of hemorrhage, so it is contra-
indicated. Bevacizumab promotes a significant improvement in
PFS and OS in patients with NSCLC.7,20,21
Rat sarcoma (RAS) membrane proteins, encoded by multi-
ple genes including Kirsten rat sarcoma virus, are involved in
growth signal transduction, and their mutations (detected in
25%-40% of NSCLCs) occur most commonly in adenocarci-
nomas.15 Historically, their targeting has not been success-
ful.5,16 Gainor et al described the mutual exclusivity between
mutations in EGFR, ALK rearrangements, and RAS
mutations.22,23
As for immunotherapy, Pembrolizumab and Nivolumab,
monoclonal antibodies directed against the programmed death
1 receptor (anti-PD1), have been approved for the treatment of
NSCLC. Two phase III clinical trials, the CheckMate 17 and
CheckMate 057, showed better results in OS compared to Doc-
etaxel in patients who progressed after platinum-containing
chemotherapy as the first line of treatment.24,25 Pembrolizu-
mab has been approved as a first-line treatment in patients with
metastatic NSCLC overexpressing PD-ligand 1 (L1) and is
associated with significantly longer PFS and OS and with fewer
adverse events than platinum-based chemotherapy.26-28 Atezo-
limumab is an anti-PD-L1 agent recently approved for meta-
static NSCLC and disease progression after or during
chemotherapy with platinum derivatives.5 The addition of Ipi-
limumab, a cytotoxic T-lymphocyte associated protein 4
(CTLA 4) inhibitor, to first-line chemotherapy failed in a phase
III trial to prolong OS compared to chemotherapy alone.29-31
Other agents currently studied are mitogen-activated protein
kinase 2 (MEK) inhibitors, BRAF inhibitors, and vaccines.7
SCLC is highly radiochemosensitive, but its prompt
response to treatments is usually also followed by early recur-
rence. Effective molecular therapies for this disease are still
lacking. A possible approach is based on delta-like 3 (DLL3)
targeting: DLL3 is highly expressed by SCLC, and treatment
with an antibody–drug conjugate therapy has shown some ini-
tial promising results, but clinical efficacy still has to be inves-
tigated in larger trials.32 Main mutations and treatments are
summarized in Table 1.
Breast cancer
Breast cancer (BC) is the second cause of cancer-related death
among women.33 Its heterogeneous nature is well known and
influences therapeutic strategies. The most important
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classification of BC is based on the expression of hormone
receptors (HRs) and on the amplification/expression of the
HER2 gene/protein;34 these molecular subtypes are:
1. luminal A (HRþ/HER2), slow growing, and less
aggressive than the others;
2. luminal B (HRþ/HER2þ), with poorer prognosis than
luminal A;
3. HER2 type (overexpression of HER2/ERBB2 onco-
gene); and
4. triple negative (HR/HER2), more aggressive, and
difficult to treat because of early resistance despite its
initial sensitivity to chemotherapy.
Luminal A and B. Endocrine therapy is the mainstay for treatment.
Drugs are generally used in combination. Tamoxifen blocks
estrogen receptors; aromatase inhibitors (letrozole, anastrozole,
exemestane) deplete estrogens by blocking conversion from
androgens; luteinizing hormone–releasing hormone (LHRH)
analogs (leuprolide and goserelin) suppress ovarian production
of estrogen; and fulvestrant is a selective estrogen degrader.34
New agents have been developed to reverse endocrine resis-
tance that usually develops in metastatic BC. Some tumors,
after development of hormonal resistance, depend on the
CDK4/6–cyclin D1 complex for proliferation. Following Food
and Drug Administration (FDA) approval, Palbociclib, Ribo-
ciclib, Abemaciclib, and CDK4/6 inhibitors are currently used
in combination for advanced BC, prolonging PFS.35-39 When
mutated, phosphatidylinositol 3-kinase-catalytic subunit p110
a is an important target for combination therapy in advanced
BC: Buparlisib, Alpeisib, Talesisib, and Pictillisib show pro-
mising effects and are currently under investigation. 40-44
Entinostat and Vorinostat, histone deacetylase (HDAC)
inhibitors, are thought to reverse hormone resistance mediated
by the loss of ER expression; they are still under investigation
with potential efficacy, if proven, when used in combination in
advanced BC.45-47 A steroid sulfatase inhibitor, Irosustat,
showed clinical benefit when administered in association with
an aromatase inhibitor: Steroid sulfatase enzymes are indeed
well expressed in hormone-dependent tumors.48 Everolimus,
an mammalian target of rapamycin (mTOR) inhibitor, has
received FDA approval for combination therapy in advanced
BC.49
Human epidermal growth factor receptors 2 type. The mainstay of
treatment includes anti-HER2 monoclonal antibodies, such as,
Trastuzumab and Pertuzumab, which act on different binding
sites. Ado-Trastuzumab emtansine is a complex of Trastuzu-
mab and a microtubule inhibitor. Lapatinib is a TKI that blocks
HER2 and EGFR pathways.34 These drugs are used alone or in
combination. Novel therapies have been developed against
acquired resistance to Trastuzumab. Buparlisib and Pilaralisib,
phosphoinositide 3-kinase (PI3K) inhibitors, showed efficacy
when administered in combination in advanced BC. The
mTOR inhibitors, such as Everolimus, Ridaforolimus, and Sir-
olimus, and Akt inhibitors, such as MK-2206, revealed promis-
ing activity in resistant HER2þ BC.34 Other targeted therapies
include inhibitors of HER-family receptors, such as Neratinib
(TKI of HER1/HER2/HER4), Patritumab (anti-HER3 mono-
clonal antibody), Margetuximab (anti-HER2), and Lonafarnib
(Farnesyl transferase Inhibitor).50-57
As for immunotherapy, Nelipepimut-S is a peptide derived
from HER2 used as a vaccine to prevent recurrence; it is being
studied in a phase IIb trial in association with Trastuzumab.58,59
Recombinant HER2 protein is a protein vaccine under investi-
gation for adjuvant and advanced treatments.60-62
Triple negative. It is theoretically the most responsive to che-
motherapy but the most difficult to treat because of the lack of
targeted therapies and the early resistance to treatments. Che-
motherapy usually involves the use of anthracyclines, taxanes,
and platinum, sometimes in combination with Bevacizumab.63
Novel therapeutic strategies, still experimental for now,
include poly(ADP-ribose) polymerase inhibitors, probably the
most important advancement, such as Olaparib, Talazoparib,
Veliparib, Niraparib, and Rucaparib34; EGFR inhibitors such
as Cetuximab64; new monoclonal antibodies such as Glemba-
tumumab;65 and TKIs such as Dasatinib.66 Main mutations and
treatments are summarized in Table 2.
Prostate Cancer
In men, prostate cancer (PC) is the second most common cause
of death as it is a neoplastic disease.4,67 Its increasing incidence
Table 1. Lung cancer.
Molecular Feature
Target of
Therapies Drug(s)
EGFR EGFR TKI Gefitinib, Erlotinib,
Afatinib, Osimertinib
HER 2/HER 4 HER 2/HER 4þ
cells
Afatinib
T790M secondary
mutation in EGFR
T790M þ cells Osimertinib
ALK-EML4 fusion
oncogene
ALK-EML4þ
cells
Crizotinib, Ceritinib,
Brigatinib, Alectinib
VEGF-A VEGF-Aþ cells Bevacizumab
PD1 PD1 þ cells Pembrolizumab,
Nivolumab
CheckMate 17 CheckMate 17 þ
cells
Docetaxel
CheckMate 057 CheckMate 057
þ cells
Docetaxel
PD-L1 PD-L1 over
expressed
cells
Pembrolizumab,
Atezolimumab
CTLA 4 CTLA 4 inhibitor Ipilimumab
Abbreviations: ALK, Anaplastic lymphoma kinase; CTLA, a cytotoxic
T-lymphocyte associated protein 4; EGFR, epithelial growth factor receptor;
EML4, echinoderm microtubule-associated protein-like 4; HER, human epider-
mal growth factor receptors; PD1, programmed death 1 receptor; TKI, tyro-
sine kinase inhibitors; VEGF, vascular endothelial growth factor.
Cofano et al 3
has been explained not only by improvements in diagnostic
methods but also by poorly defined environmental factors;
moreover, androgen hormones have a prominent role in the
development of PC.68 Androgen deprivation therapy is indeed
the mainstay of treatment, used as first-line approach for
patients with advanced and metastatic PC.69 Blockade of
androgen pathways can be obtained with 3 different treat-
ments70,71: (1) LHRH ligands, in the form of agonists down-
regulating LHRH receptors (Goserelin, Leuproline, and
Triptorelin) or antagonists such as Abarelix and Degarelix;
(2) blockade of androgen synthesis, mostly inhibiting the
upregulated enzyme CYP17 with abiraterone or with Ketoco-
nazole; (c) antiandrogens that antagonize the androgen recep-
tor (AR), such as cyproterone acetate, bicalutamide,
flutamide, nilutamide, and enzalutamide. The use of these
agents in combination with Docetaxel has recently shown
benefit in terms of OS.72
Tumor progression to the androgen-resistant (or castration-
resistant) stage is generally lethal and characterized clinically
by bone metastases.73 The mechanisms of resistance generally
involve androgen pathways and include the overexpression
and/or mutation of the AR, the upregulation of AR coactiva-
tors, the activation of AR by tyrosine kinase receptors linking
the androgen-regulated pathway with the growth factor signal-
ing pathways and the intratumoral synthesis of active andro-
gens.68 In Docetaxel-resistant PC, Cabazitaxel showed
promising results in terms of OS when compared to Mitoxan-
trone.74 Some new options for therapy of metastatic tumor have
been specifically targeted to bone lesions, which are the most
common PC metastases. Bisphosphonates inhibit osteoclast
activity and bind hydroxyapatite, preventing loss of bone struc-
ture and reducing resorption. Thus, they are able to delay clin-
ical consequences of bone involvement.75 Denosumab inhibits
osteoclast proliferation, function, and survival by binding to the
receptor activator of nuclear factor kappa-B ligand, therefore
delaying functional consequences of bone involvement.76 A
radiomolecule, radium 223, binds to bone and promotes apop-
tosis in the tumor, improving OS.77
The era of immunotherapy also involved PC. Vaccine-based
strategies are currently under investigation. Sipuleucel-T is the
first FDA-approved vaccine that uses prostatic acid phospha-
tase as tumor antigen. Survival improvement ranges from 4 to
13 months.78-81
Checkpoint inhibition is another focus for immunotherapy.
Primary targets are CTLA-4 (Ipilimumab), PD1, and the PD1
ligands PD-L1/PD-L2 (Nivolumab, Pembrolizumab, and Ate-
zolizumab).82 In 2017, pembrolizumab was approved for the
treatment of solid metastatic tumors with mismatch repair
impairment. Cetuximab, Gefitinib, Erlotinib, and Lapatinib
have also been studied.4 New immunotherapy strategies use
engineered immune cells already successful in patients with
leukemia or lymphoma: Immune cells are isolated from the
patient, engineered to express a chimeric protein composed
by a tumor-recognizing antibody region and a T-cell activation
domain and then grafted back into the patient (Chimeric Anti-
gen Receptor T cell [CAR-T] therapy).82,83 Trials with engi-
neered cells for PC are now underway.84,85 Liver X receptors
have recently been proposed as therapeutic targets in resistant
PC because of their ability to control apoptosis and modulate
androgen and estrogen receptors, with promising results in cell
lines and animal models.82 Main mutations and treatments are
summarized in Table 3.
Melanoma
Incidence rates of melanoma are still increasing, with excessive
ultraviolet radiation exposure as the only known environmental
risk factork.86 Genetic factors also play a crucial role in deter-
mining individual risk.87,88
Only 10 years ago metastatic melanoma was, among the
most common types of cancer, the one with the poorest prog-
nosis because of the lack of therapeutic strategies and effective
chemotherapeutic drugs. New targeted therapies have
Table 2. Breast cancer.
Molecular Feature Target of Therapies Drug(s)
Estrogen Estrogen receptor Tamoxifen
Aromatase Aromatase Letrozole, anastrozole,
exemestane
Ovarian estrogens Luteinizing
hormone-
releasing
hormone analogs
Leuprolide, Goserelin
Complex CDK4/
6–cyclin D1
Complex CDK4/6–
cyclin D1 þ cells
Palbociclib, Ribociclib and
Abemaciclib
PI3K-CA PI3K-CA mutated
cells
Buparlisib, Alpeisib,
Talesisib, Pictillisib
Loss of ER
expression
Reverse hormone
resistance
Entinostat and Vorinostat,
Histone Deacetylase
(HDAC) Inhibitors
mTOR mTOR inhibitor Everolimus, Ridaforolimus,
Sirolimus
Steroid sulfatase Steroid sulfatase
enzymes
Irosustat
HER 2 HER 2 þ cells Trastuzumab, Pertuzumab
HER2 and EGFR
pathways
HER2 þ cells,
EGFR þ cells
Lapatinib
Akt inhibitor Akt inhibitor þ
cells
MK-2206
HER-family
receptors
inhibitors
TKI of HER1/2/3/4,
farnesyl
transferase
inhibitor
Neratinib, Patritumab,
Margetuximab,
Lonafarnib
HER2 analogues HER2 þ cells Nelipepimut-S; dHER2
Poly(ADP-ribose)
polymerase
(PARP)
Inhibitors
PARP þ cells Olaparib, Talazoparib,
Veliparib, Niraparib,
Rucaparib
EGFR inhibitors EGFR
overexpressed
cells
Cetuximab
Abbreviations: dHER2, recombinant HER2 protein; EGFR, epithelial growth
factor receptor; HER, human epidermal growth factor receptors; mTOR,
mammalian target of rapamycin; PI3K-CA, phosphatidylinositol 3-kinase-
catalytic subunit.
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revolutionized prognosis in these patients achieving a longer
survival and greater control of the disease.89
A real milestone has been the discovery of BRAF gene
mutation (V600) in more than half of melanoma cell lines.90
The BRAF V600 mutation determines constitutive MAPK
pathway activation and proliferation, a key point for tumor
growth.89
In patients with BRAF mutation, the use of BRAF inhibitors
(Vemurafenib and Dabrafenib) has thus changed therapeutic
strategies.91,92 Recently, a new BRAF inhibitor, Encorafenib,
showed greater benefits compared to Vemurafenib.93 A com-
bination of BRAF inhibitors with mitogen-activated protein
kinase kinase (MEK) inhibitors—like Trametinib, Cobimeti-
nib, or Binimetinib—resulted in longer PFS and OS, compared
to BRAF inhibitors alone, and also reduced their toxicity. In a
quarter of patients, this new strategy is able to offer even a very
long control of the disease (2-3 years in advanced disease)
before drugs resistance arises.94-98
As for immunotherapy, Ipilimumab (anti-CTLA-4) was
shown to improve OS in patients with metastatic melanoma,
and it thus received regulatory approval in 2011.99,100 Long-
lasting survival was observed in 20% of cases, even when no
complete response was reported, highlighting the potentially
curative efficacy of immunotherapy as never described
before.101 Later, in 2014, Nivolumab and Pembrolizumab
(anti-PD-1) were approved as first-line treatment for patients
with wild-type BRAF and as first or second line for patients
with BRAF mutation. This is due to the promising results of 2
phase III studies comparing Nivolumab to Dacarbazine and
Pembrolizumab to Ipilimumab, showing better control of the
disease in both cases.102,103 Anti-CTLA-4 and anti-PD-1 drugs
have also been studied in combination, with better results in
terms of PFS and OS than with each drug alone.104 Because of
toxicity, further studies are needed to define which patients
would really benefit from the combination and which would
experience increased adverse effects without a significant clin-
ical benefit.
Another field of therapy is that of oncolytic viruses, which
reaches in melanoma its most advanced example. Talimogen
laherparepvec (T-VEC) is a herpes simplex virus type 1 able to
promote, after genetic engineering, tumor cells lysis and
immune responses after antigen release and granulocyte-
macrophage colony-stimulating factor. It was approved in
2015 for local treatment of recurrence after surgery.105 Opti-
mization of therapy with T-VEC in combination with immu-
notherapy has been explored with promising results. Other
oncolytic viruses, vaccines, and a metabolic modulation
approach (epacadostat) are currently under investigation.106-
109 Main mutations and treatments are summarized in Table 4.
Renal Cell Cancer
Renal cell carcinoma is a common cause of widespread metas-
tases at diagnosis.110 The median OS was very poor before the
introduction of targeted therapy, when interleukin-2 and inter-
feron a were used as immunotherapy. The scenario dramati-
cally changed in the mid-2000s with the introduction of
targeted therapy against VEGF: new strategies included TKIs
such as Sunitinib (the most frequently used), Pazopanib, Axi-
tinib, or Sorafenib or monoclonal antibodies such as Bevacizu-
mab.110-115 Other studies concentrated on Temsirolimus or
Everolimus.116,117
In the last few years, new trials investigated immunother-
apy. CheckMate 214 showed better results in terms of objective
response rate, PFS, and OS with the use of Nivolumab plus
Ipilimumab compared to Sunitinib.118 CABOSUN119-121
Table 3. Prostate cancer.
Molecular
Feature Target of Therapies Drug(s)
Androgen
pathways
LHRH ligands Goserelin, Leuproline,
Triptorelin, Abarelix,
Aegarelix;
Androgen
pathways
Enzyme CYP17 Abiraterone,
Ketoconazole;
Androgen
pathways
Androgen receptor (AR) cyproterone acetate,
bicalutamide,
flutamide, nilutamide,
enzalutamide.
Osteoclast
proliferation
Receptor activator of
nuclear factor kappa-B
ligand (RANKL)
Denosumab
Checkpoint
inhibitors
CTLA-4, PD1, PD1 ligands
PD-L1/PD-L2
Ipilimumab, nivolumab,
pembrolizumab,
atezolizumab
Abbreviations: CTLA, a cytotoxic T-lymphocyte associated protein 4; LHRH,
luteinizing hormone–releasing hormone; PD1, programmed death 1 receptor.
Table 4. Melanoma.
Molecular Feature Target of Therapies Drug(s)
BRAF inhibitors BRAF þ cells Vemurafenib,
Dabrafenib,
Encorafenib,
BRAF inhibitors with
mitogen-activated
protein kinase kinase
(MEK) inhibitors
BRAF inhibitors with
mitogen-activated
protein kinase kinase
(MEK) inhibitors þ
cells
Trametinib,
cobimetinib or
binimetinib
CTLA-4 CTLA-4 þ cells Ipilimumab
PD-1 PD-1 þ cells Nivolumab,
Pembrolizumab,
Dacarbazine
Tumor cell lysis and
immune responses
after antigen release
and granulocyte-
macrophage colony-
stimulating factor
(GM-CSF).
Immune cells Talimogen
laherparepvec
(T-VEC)
Abbreviations: CTLA, a cytotoxic T-lymphocyte associated protein 4; PD1,
programmed death 1 receptor; T-VEC, Talimogen laherparepvec.
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revealed benefits with the use of Cabozantinib. Many trials are
currently underway, with other new regimens involving the
mentioned drugs or others such as Atezolizumab, Pembrolizu-
mab, Avelumab, or Lenvatinib.122 Vaccines are also being
studied with different targets.123,124 Main mutations and treat-
ments are summarized in Table 5.
Other Tumors
Thyroid cancer. A small percentage of patients with differen-
tiated thyroid carcinoma (DTC, 15%-20%), anaplastic carci-
noma, and medullary thyroid carcinoma (MTC, 30%) could
experience resistance after standard therapy.125 The use of Sor-
afenib and Lenvantinib for DTC and Vandetanib and Cabozan-
tinib for MTC, with their ability to block the MAPK pathway,
has changed their prognosis.125-127 However, further resistance
to these drugs has been recorded and explained with the activa-
tion of parallel pathways. After scientific advances regarding
the understanding of these mechanisms, new strategies are cur-
rently under investigation, such as targeting the PI3K pathway,
ALK translocations, HER2/3 receptors, the restoration to radio-
active iodine sensitivity, immunotherapy (anti CTLA-4 and
anti-PD-1), or vaccines.125 Main mutations and treatments are
summarized in Table 6.
Hepatocellular carcinoma. Sorafenib was approved in 2007 and
remained the only treatment for advanced hepatocellular carci-
noma until the approval of Lenvatinib.128-130 For second-line
therapies, only in the last 2 years, new strategies have become
the standard of care, with the recent introduction of Regorafe-
nib and Nivolumab. Cabozantinib and Ramucirumab (that bind
to VEGFR-2) also showed benefits in advanced disease.131
Various clinical trials with immunotherapy are currently under-
way. CAR-T therapy has shown promising, although only
preliminary, results.132,133 Main mutations and treatments are
summarized in Table 7.
Colorectal cancer. Conventional chemotherapy still retains its
role and efficacy in slowly progressing or metastatic disease
as first-line treatment and involves the use of fluoropyrimidine,
oxaliplatin, and irinotecan.134 Strong evidence suggests that
biological agents, targeting VEGF or EGFR pathways (Beva-
cizumab; Cetuximab, and Panitumumab), also constitute a
valuable option for first-line treatment in combination with
conventional chemotherapy. The RAS mutation status is a rou-
tinely used test to investigate the efficacy of anti-EGFR anti-
bodies. TAS102 is a synthetically engineered fluoropyrimidine
that showed to prolong PFS and OS.135 New targeted strategies
include analysis of mismatch repair function to predict benefits
using checkpoint inhibitors, BRAF mutations, and HER2
amplifications.133 Current studies investigate Regorafenib,
Nivolumab, Pembrolizumab, Ipilimumab, Trastuzumab, and
Pertuzumab.134,136-142 Main mutations and treatments are sum-
marized in Table 8.
Lymphohematopoietic malignancies. Even if not strictly consid-
ered as metastases, spinal localizations of myeloma and non-
Hodgkin (NH) lymphoma deserve a concise discussion about
therapeutic advancements.
Myeloma. Significant advancements improved the outcome of
patients with myeloma in the last decade.143 The development
of proteasome inhibitors (Bortezomib, Carfilzomib, and Ixazo-
mib) and immunotherapy significantly changed survival and
helped improving depth and duration of response.144,145 One
of the first immunotherapies in myeloma was allogenic stem
cell transplantation, associated with a high rate of treatment-
related mortality.143 This is why novel and well-tolerated forms
of immunotherapies have been approved and currently used
while others are under clinical investigations. Among them,
Table 5. Renal Cell cancer.
Molecular
feature target of therapies drug(s)
VEGF TKI, monoclonal
antibodies anti
VEGF
Sunitinib, Pazopanib, Atixinib,
Sorafenib, bevacizumab
CheckMate
214
Ab-antiCheckMate
214
Nivolumab, Ipilimumab,
Sunitinib
Abbreviations: TKI, tyrosine kinase inhibitors; VEGF, vascular endothelial
growth factor.
Table 6. Thyroid cancer.
Molecular
Feature
Target of
Therapies Drug(s)
MAPK
pathway
MAPK Sorafenib, Levantinib, Vandetanib,
Cabozantinib
Abbreviation: MAPK, mitogen-activated protein kinase.
Table 7. Hepatocellular carcinoma.
Molecular
Feature
Target of
Therapies Drug(s)
VEGFR-2 VEGFR-2 þ
cells
Regorafenib, Nivolumab. Cabozantinib,
Ramucirumab
MAPK
pathway
MAPK Sorafenib, Lenvatinib
Abbreviations: MAPK, mitogen-activated protein kinase; VEGFR, vascular
endothelial growth factor receptor.
Table 8. Colorectal cancer.
Molecular Feature Target of Therapies Drug(s)
VEGF pathway VEGF þ cells Bevacizumab
EGFR pathway EGFR þ cells Cetuximab, Panitumumab
Abbreviations: EGFR, epithelial growth factor receptor; VEGF, vascular
endothelial growth factor.
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immunomodulatory drugs (such as Thalidomide, Lenalido-
mide, and Pomalidomide, respectively first, second, and third
generation) are currently used in several treatment combina-
tions.146-150 Two main monoclonal antibodies have been stud-
ied 143,151-154: Elotuzumab, against the signaling lymphocytic
activation molecule F7 (SLAMF7), has been studied in com-
bination with Bortezomib and Dexamethasone resulting in
improved OS. Daratumumab, against CD38, is currently
approved as monotherapy in relapsed/refractory myeloma or
in combination with Bortezomib–dexamethasone, Pomalido-
mide–dexamethasone, or with Bortezomib–Melphalan–Predni-
sone. Novel immunotherapies, currently under investigations
with promising results, involve chimeric antigen receptor T
cells (anti-BCMA CAR T-cells), bispecific antibodies such as
bispecific T-cell engagers, immune checkpoint inhibitors (PD-
1/PD-L1 inhibitors like Pembrolizumab), and dendritic cell
vaccination.143,155-157 Main mutations and treatments are sum-
marized in Table 9.
Non-Hodgkin Lymphoma. The vast majority of mortality in NH
Lymphoma is caused by aggressive subtypes of B- and T-cell
NH Lymphoma. These diseases are very heterogeneous in their
molecular pattern. This is why novel therapies provide only
limited benefits since now despite the acquisition of knowledge
of a large number of molecular targets. Nevertheless, new
studies seem to identify subtypes able to respond differentially
to specific therapies for NH Lymphoma.158
New agents have been developed following different path-
ways and depending on the unique biology of the tumors157-167:
Among the others, Fostamatinib and Ibrutinib target the B-cell
receptor (Syk and Btk); Venetoclax acts in the apoptosis pro-
cess (BCL-2 as target); Nivolumab (anti-PD-1 monoclonal
antibody) works as a checkpoint inhibitor; Duvesilib,
MK2206, and Everolimus target the PI3K/AKT/mTOR com-
plex; and RG6146, Tazemetostat, and Romidepsin work
modifying the epigenetic regulation (BET BRD, EZH 2, and
HDAC). These agents showed promising results in different
trials. Probably, different molecular aberrations and biological
subgroups, as well as the understanding of their role in the
single patients, will provide a better rationale for therapy in
the next years.158 Main mutations and treatments are summar-
ized in Table 10.
Conclusion
Changing Approach in Spine Metastases
Since patients with cancer are living longer, it is well known
that the number of patients with spinal metastases will continue
to grow. The advent of targeted therapy in the last 10 years has
revolutionized the life expectancy of these patients, and further
improvements are expected in the coming decades. The goal
for the cancer team is to not neglect the clinical and radiologi-
cal status of patients with spinal metastases. Surgical treatment
and radiotherapy of spinal metastases play a crucial role in the
therapeutic approach as confirmed by several authors which
collected clinical results of this last decade of targeted strate-
gies. Furthermore, complications related to spinal metastases
often limit further treatments because of the resulting signifi-
cant clinical impairment.
The implications of the remarkable therapeutic novelties in
the treatment of spinal metastases are large, according to the
existing literature.2,168-170 These patients should receive the
maximal safe treatment to improve the quality of their poten-
tially still long residual life, taking into account their clinical
conditions and systemic status. Patients treated for spinal
metastases should be referred to centers with sufficient expe-
rience and interdisciplinary networks. The experience and
skills of several different medical professionals are mandatory:
An interdisciplinary oncology team represents the winning
strategy in the therapeutic approach.
As about surgery, every effort must be focused on prevent-
ing spinal cord damage in the affected segments and patholo-
gical collapses due to instability, since paraplegia dramatically
Table 9. Myeloma.
Molecular
Feature Target of Therapies Drug(s)
Monoclonal
antibodies
Signaling lymphocytic activation
molecule F7 (SLAMF7)
Elotuzumab
Monoclonal
antibodies
CD38 Daratumumab
Chimeric antigen
receptor
T-cells
Anti-BCMA CAR T-cells -
Chimeric antigen
receptor T
cells
Bispecific antibodies (BsAbs) like
Bispecific T-cell engagers
(BiTEs)
-
Immune-
checkpoint
inhibitors
PD-1/PD-L1 inhibitors Pembrolizumab
Dendritic cell
vaccination
- -
Abbreviation: PD1, programmed death 1 receptor.
Table 10. Non-Hodgkin Lymphoma.
Molecular
Feature Target of Therapies Drug(s)
Target the B-cell
receptor
Syk and Btk Fostamatinib, Ibrutinib
Apoptosis
process
BCL-2 Venetoclax
Checkpoint
inhibitor
Anti-PD-1 monoclonal
antibody
Nivolumab
mTOR PI3K/AKT/mTOR
complex
Duvesilib, MK2206, and
Everolimus
Epigenetic
regulation
BET BRD, EZH 2,
Histone deacetylase
RG6146, Tazemetostat,
and Romidepsin
Abbreviations: mTOR, mammalian target of rapamycin; PD1, programmed
death 1 receptor; PI3K, phosphatidylinositol 3-Kinase.
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reduces prognosis representing thus a defeat for the oncology
team. Based on the histopathology and the molecular pattern of
the tumor, different surgical strategies could be performed.
Separation surgery is a valid and recognized therapeutic step
in case of epidural compression to allow the best radiation
treatment for high radiosensitive tumors or before radiosur-
gery. The feasibility and the oncological meaning of aggressive
cytoreductive procedures such as en bloc corpectomies in sin-
gle locations and in patients with a favorable tumor profile
should be further investigated to strengthen evidence and
should be compared to radiosurgical treatments. More aggres-
sive treatments could also be justified with the increase in life
expectancy to face spinal instability and prevent mechanical
damage.
Modern technological aids available for surgery helped to
reduce postoperative complications and hospitalization. Every
modern spinal oncological surgical center should consider and
promote the use of the most innovative techniques: instruments
for minimally invasive approaches, percutaneous and transfas-
cial systems, and navigation. Among new strategies, carbon
fiber instrumentation represents an excellent synthesis between
surgical and radio therapeutic needs and should be adopted by
all centers supported by long-term studies.
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